- Home
- ZENV vs CUE Comparison
ZENV vs CUE Comparison
Compare ZENV & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CUE
- Stock Information
- Founded
- ZENV 2005
- CUE 2014
- Country
- ZENV Brazil
- CUE United States
- Employees
- ZENV N/A
- CUE N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- CUE Health Care
- Exchange
- ZENV Nasdaq
- CUE Nasdaq
- Market Cap
- ZENV 70.8M
- CUE 61.1M
- IPO Year
- ZENV 2021
- CUE 2018
- Fundamental
- Price
- ZENV $1.35
- CUE $0.77
- Analyst Decision
- ZENV
- CUE Strong Buy
- Analyst Count
- ZENV 0
- CUE 2
- Target Price
- ZENV N/A
- CUE $3.00
- AVG Volume (30 Days)
- ZENV 27.2K
- CUE 270.3K
- Earning Date
- ZENV 11-17-2025
- CUE 11-12-2025
- Dividend Yield
- ZENV N/A
- CUE N/A
- EPS Growth
- ZENV N/A
- CUE N/A
- EPS
- ZENV N/A
- CUE N/A
- Revenue
- ZENV $201,426,369.00
- CUE $8,286,000.00
- Revenue This Year
- ZENV $6.49
- CUE N/A
- Revenue Next Year
- ZENV $3.82
- CUE N/A
- P/E Ratio
- ZENV N/A
- CUE N/A
- Revenue Growth
- ZENV 24.80
- CUE N/A
- 52 Week Low
- ZENV $1.02
- CUE $0.54
- 52 Week High
- ZENV $3.03
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ZENV 44.84
- CUE 41.54
- Support Level
- ZENV $1.29
- CUE $0.68
- Resistance Level
- ZENV $1.41
- CUE $0.81
- Average True Range (ATR)
- ZENV 0.06
- CUE 0.04
- MACD
- ZENV -0.00
- CUE -0.01
- Stochastic Oscillator
- ZENV 40.74
- CUE 20.26
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.